About Previse
Previse is a company based in Baltimore (United States) founded in 2018 by Dan Lunz and Stephen Meltzer was acquired by Castle Biosciences in May 2025. It operates as a HealthTech. Previse has raised $5.39 million across 3 funding rounds from investors including Castle Biosciences and National Institute of Diabetes and Digestive and Kidney Diseases. Previse offers products and services including Esopredict. Previse operates in a competitive market with competitors including PAVmed, Cyted, Lucid Diagnostics, BeamLine Diagnostics and CapNostics, among others.
- Headquarter Baltimore, United States
- Founders Dan Lunz, Stephen Meltzer
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Castle Biosciences
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$5.39 M (USD)
in 3 rounds
-
Latest Funding Round
$1.8 M (USD), Grant
Oct 11, 2023
-
Investors
Castle Biosciences
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Castle Biosciences
(May 05, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Previse
Previse offers a comprehensive portfolio of products and services, including Esopredict. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Personalized guidance for Barrett’s esophagus surveillance is provided.
Funding Insights of Previse
Previse has successfully raised a total of $5.39M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.8 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $1.8M
-
First Round
First Round
(17 Dec 2019)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Grant - Previse | Valuation |
investors |
|
| Mar, 2023 | Amount | Seed - Previse | Valuation |
investors |
|
| Dec, 2019 | Amount | Seed - Previse | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Previse
Previse has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Castle Biosciences and National Institute of Diabetes and Digestive and Kidney Diseases. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research and health information on diabetes and kidney diseases are provided by NIDDK.
|
Founded Year | Domain | Location | |
|
Diagnostic tests for cancer prognosis are provided.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Previse
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Previse
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Previse Comparisons
Competitors of Previse
Previse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PAVmed, Cyted, Lucid Diagnostics, BeamLine Diagnostics and CapNostics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of medical devices and biomarkers to detect various diseases
|
|
| domain | founded_year | HQ Location |
Non-endoscopic diagnostics for early gastrointestinal disease detection are developed.
|
|
| domain | founded_year | HQ Location |
Diagnostic kits for esophageal cancer biomarkers are developed.
|
|
| domain | founded_year | HQ Location |
Offers bedside pre-screening technology solutions for cancer detection.
|
|
| domain | founded_year | HQ Location |
FDA-cleared swallowable device is used for non-endoscopic GI screening.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Previse
Frequently Asked Questions about Previse
When was Previse founded?
Previse was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Previse located?
Previse is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Who is the current CEO of Previse?
Dan Lunz is the current CEO of Previse. They have also founded this company.
Is Previse a funded company?
Previse is a funded company, having raised a total of $5.39M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.39M, raised on Dec 17, 2019.
What does Previse do?
Solutions for earlier cancer detection are developed by Previse, focusing initially on esophageal cancer. Proprietary epigenetic biomarkers and data science are utilized to support diverse clinical studies globally. Precision medicine approaches are employed to predict and prevent cancer progression, particularly for conditions like Barretts esophagus. The healthcare sector is primarily targeted with innovative diagnostic tools.
Who are the top competitors of Previse?
Previse's top competitors include Lucid Diagnostics, PAVmed and Cyted.
What products or services does Previse offer?
Previse offers Esopredict.
Who are Previse's investors?
Previse has 2 investors. Key investors include Castle Biosciences, and National Institute of Diabetes and Digestive and Kidney Diseases.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.